VP of Beike Pharmaceuticals provides bleak analysis of cancer therapy in China.

In a talk at China’s 18th Biopharmaceutical Drug Development Forum held in Beijing, VP Luo Lu SONG stated that China may have as many as 25 % of the world’s cancer patients, but therapy is mostly based on traditional chemotherapy, and Chinese patients share only a few percent of the global cancer therapy market based on modern targeted therapy or antitumor antibodies.